Product Description
An anti-PD-1, anti-TIGIT, IL-15/IL-15Rα bispecific fusion protein independently developed by Huiyu Haiyue for solid tumors. (Sourced from: https://www.moomoo.com/news/post/40762533/huiyu-pharmaceutical-688553-sh-injectable-hy07121-obtains-drug-clinical-trial?level=1&data_ticket=1724423598756466)
Mechanisms of Action: PD-1 Inhibitor,TIGIT Inhibitor,IL15 Inhibitor
Novel Mechanism: Yes
Modality: Fusion Protein
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|